MX391600B - Piridinas sustituidas como inhibidores de adn metiltransferasa-1 (dnmt1) - Google Patents
Piridinas sustituidas como inhibidores de adn metiltransferasa-1 (dnmt1)Info
- Publication number
- MX391600B MX391600B MX2018015483A MX2018015483A MX391600B MX 391600 B MX391600 B MX 391600B MX 2018015483 A MX2018015483 A MX 2018015483A MX 2018015483 A MX2018015483 A MX 2018015483A MX 391600 B MX391600 B MX 391600B
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- dnmt1
- compound
- directed
- inhibitors
- Prior art date
Links
- 102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 title abstract 5
- 150000003222 pyridines Chemical class 0.000 title abstract 2
- 101000931098 Homo sapiens DNA (cytosine-5)-methyltransferase 1 Proteins 0.000 title 2
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 108010009540 DNA (Cytosine-5-)-Methyltransferase 1 Proteins 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000007056 sickle cell anemia Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229940124639 Selective inhibitor Drugs 0.000 abstract 1
- 208000018020 Sickle cell-beta-thalassemia disease syndrome Diseases 0.000 abstract 1
- 206010043391 Thalassaemia beta Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000034737 hemoglobinopathy Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662349227P | 2016-06-13 | 2016-06-13 | |
| US201662393256P | 2016-09-12 | 2016-09-12 | |
| US201662412343P | 2016-10-25 | 2016-10-25 | |
| PCT/IB2017/053511 WO2017216727A1 (en) | 2016-06-13 | 2017-06-13 | Substituted pyridines as inhibitors of dnmt1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018015483A MX2018015483A (es) | 2019-03-18 |
| MX391600B true MX391600B (es) | 2025-03-21 |
Family
ID=59239935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018015483A MX391600B (es) | 2016-06-13 | 2017-06-13 | Piridinas sustituidas como inhibidores de adn metiltransferasa-1 (dnmt1) |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10975056B2 (enExample) |
| EP (1) | EP3468953B1 (enExample) |
| JP (1) | JP7051829B2 (enExample) |
| KR (1) | KR20190017030A (enExample) |
| CN (1) | CN109563043B (enExample) |
| AU (1) | AU2017283790B2 (enExample) |
| CA (2) | CA3026226A1 (enExample) |
| CL (1) | CL2018003577A1 (enExample) |
| CO (1) | CO2018013717A2 (enExample) |
| CR (1) | CR20180580A (enExample) |
| DO (1) | DOP2018000273A (enExample) |
| ES (1) | ES2993451T3 (enExample) |
| IL (1) | IL263163B (enExample) |
| JO (1) | JOP20180120A1 (enExample) |
| MA (1) | MA45244A (enExample) |
| MX (1) | MX391600B (enExample) |
| PE (1) | PE20190971A1 (enExample) |
| PH (1) | PH12018502633B1 (enExample) |
| SG (1) | SG11201809559UA (enExample) |
| WO (2) | WO2017216727A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108137641B (zh) | 2015-08-13 | 2022-04-01 | 默沙东公司 | 作为sting激动剂的环状双核苷酸化合物 |
| US11453697B1 (en) | 2015-08-13 | 2022-09-27 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
| NZ748641A (en) | 2016-06-13 | 2020-04-24 | Gilead Sciences Inc | Fxr (nr1h4) modulating compounds |
| CA2968836C (en) | 2016-06-13 | 2025-09-02 | Gilead Sciences, Inc. | FXR MODULATING COMPOUNDS (NR1H4) |
| JP6636673B2 (ja) | 2016-10-04 | 2020-01-29 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | ＳＴＩＮＧアゴニストとしてのベンゾ［ｂ］チオフェン化合物 |
| ES2982801T3 (es) | 2017-03-28 | 2024-10-17 | Gilead Sciences Inc | Combinaciones terapéuticas para el tratamiento de las enfermedades hepáticas |
| US11466047B2 (en) | 2017-05-12 | 2022-10-11 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
| AU2018311965A1 (en) | 2017-08-04 | 2020-02-13 | Merck Sharp & Dohme Llc | Combinations of PD-1 antagonists and benzo[b]thiophene sting antagonists for cancer treatment |
| MA49772A (fr) | 2017-08-04 | 2021-04-21 | Merck Sharp & Dohme | Agonistes benzo[b]thiophène de sting pour le traitement du cancer |
| WO2019072143A1 (zh) * | 2017-10-11 | 2019-04-18 | 上海迪诺医药科技有限公司 | 4-氨基吡啶衍生物、其药物组合物、制备方法及应用 |
| WO2019125974A1 (en) | 2017-12-20 | 2019-06-27 | Merck Sharp & Dohme Corp. | Cyclic di-nucleotide compounds as sting agonists |
| US11702430B2 (en) | 2018-04-03 | 2023-07-18 | Merck Sharp & Dohme Llc | Aza-benzothiophene compounds as STING agonists |
| US10793557B2 (en) | 2018-04-03 | 2020-10-06 | Merck Sharp & Dohme Corp. | Sting agonist compounds |
| KR102692309B1 (ko) | 2019-01-15 | 2024-08-07 | 길리애드 사이언시즈, 인코포레이티드 | Fxr (nr1h4) 조정 화합물 |
| WO2020172075A1 (en) | 2019-02-19 | 2020-08-27 | Gilead Sciences, Inc. | Solid forms of fxr agonists |
| CN111662283B (zh) * | 2019-03-07 | 2021-11-16 | 湖南化工研究院有限公司 | 咪唑并吡啶类化合物及其中间体、制备方法与应用 |
| WO2022076563A1 (en) * | 2020-10-07 | 2022-04-14 | University Of Florida Research Foundation, Incorporated | Macrocyclic compounds and methods of treatment |
| CA3212345A1 (en) * | 2021-03-02 | 2022-09-09 | Glaxosmithkline Intellectual Property Development Limited | Substituted pyridines as dnmt1 inhibitors |
| CN113502265B (zh) * | 2021-05-25 | 2024-05-28 | 昭泰英基生物医药（香港）有限公司 | 将t细胞重编程为类nk细胞的诱导剂及其应用 |
| CN113278021B (zh) * | 2021-05-29 | 2022-09-23 | 天津全和诚科技有限责任公司 | 1,7-二氮杂螺[3.5]壬烷-7-甲酸叔丁酯及其草酸盐的制备方法 |
| MX2024004801A (es) | 2021-10-19 | 2024-06-28 | Akirabio Inc | Composiciones que comprenden análogos de 2'- desoxicitidina, y uso de las mismas para el tratamiento de anemia de células falciformes, talasemia y cánceres. |
| CN114230459A (zh) * | 2021-12-10 | 2022-03-25 | 武汉九州钰民医药科技有限公司 | 一种化合物的制备方法及分析检测方法 |
| WO2023192629A1 (en) * | 2022-04-01 | 2023-10-05 | Herophilus, Inc. | Induction of mecp2 expression by dna methyl transferase inhibitors |
| WO2024156288A1 (en) * | 2023-01-29 | 2024-08-02 | Shanghai Kygent Pharmaceutical Co., Ltd | Dnmt1 inhibitors, pharmaceutical compositions, and therapeutic applications |
| WO2025006902A2 (en) * | 2023-06-29 | 2025-01-02 | Dana-Farber Cancer Institute, Inc. | Synthesis and in vitro characterization of proteolysis targeting chimeras (protacs) for degradation of dna methyltransferase 1 (dnmt1) |
| WO2025085756A1 (en) * | 2023-10-18 | 2025-04-24 | University Of Florida Research Foundation, Incorporated | Macrocyclic compounds and methods of treatment |
| WO2025190286A1 (en) * | 2024-03-12 | 2025-09-18 | Shanghai Kygent Pharmaceutical Co., Ltd | Pyridine compounds, pharmaceutical compositions, and applications |
| CN119306700B (zh) * | 2024-08-28 | 2026-06-02 | 山东大学 | Dnmt1-hdac双靶点抑制剂及其制备方法和应用 |
| WO2026164985A1 (en) | 2025-01-28 | 2026-08-06 | Icahn School Of Medicine At Mount Sinai | Dna methyltransferase 1 (dnmt1) monovalent degraders |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2030875C (en) | 1990-11-26 | 2002-07-02 | Alan R.P. Paterson | Methods and probes for detecting nucleoside transporter and method for producing the probes |
| CA2075154A1 (en) | 1991-08-06 | 1993-02-07 | Neelakantan Balasubramanian | Peptide aldehydes as antithrombotic agents |
| WO1994022853A1 (en) | 1993-03-26 | 1994-10-13 | Shell Internationale Research Maatschappij B.V. | Herbicidal 1-heteroaryl pyrazolidin-3,5-diones |
| TR199801255T2 (xx) | 1995-12-29 | 1998-10-21 | Smithkline Beecham Corporation | Vitronektin resept�r antagonistleri. |
| WO1997024124A1 (en) | 1995-12-29 | 1997-07-10 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
| DE19947154A1 (de) * | 1999-10-01 | 2001-10-04 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
| WO2001044172A1 (en) | 1999-12-15 | 2001-06-21 | Axys Pharmaceuticals, Inc. | Salicylamides as serine protease and factor xa inhibitors |
| US6794506B2 (en) | 2000-07-21 | 2004-09-21 | Elan Pharmaceuticals, Inc. | 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 |
| US20030166554A1 (en) | 2001-01-16 | 2003-09-04 | Genset, S.A. | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists |
| DE10110754A1 (de) * | 2001-03-07 | 2002-09-19 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
| DE10134481A1 (de) * | 2001-07-16 | 2003-01-30 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung |
| DE10238113A1 (de) * | 2001-12-11 | 2003-06-18 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung |
| TW200406370A (en) | 2002-06-28 | 2004-05-01 | Syngenta Participations Ag | 4-(3,3-Dihalo-allyloxy)phenoxy alkyl derivatives |
| AR043048A1 (es) | 2002-08-30 | 2005-07-13 | Syngenta Participations Ag | Derivados de 4-(3,3-dihalo- aliloxi) fenol con propiedades pesticidas |
| US6930117B2 (en) | 2002-11-09 | 2005-08-16 | The Procter & Gamble Company | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones |
| AR042344A1 (es) | 2002-12-11 | 2005-06-15 | Syngenta Participations Ag | Derivados de 4-(3,3 - dihalo - aliloxi) fenol con propiedades pesticidas |
| SE0203712D0 (sv) | 2002-12-13 | 2002-12-13 | Astrazeneca Ab | Novel compounds |
| JP4895806B2 (ja) | 2003-04-09 | 2012-03-14 | エクセリクシス， インク． | Ｔｉｅ−２モジュレータと使用方法 |
| ATE556067T1 (de) | 2003-05-20 | 2012-05-15 | Ajinomoto Kk | Modulatoren des vanilloid rezeptors |
| CN1856307A (zh) | 2003-09-23 | 2006-11-01 | 默克公司 | 喹啉钾通道抑制剂 |
| AU2011253934C1 (en) | 2004-06-17 | 2013-08-22 | Cytokinetics, Inc. | Substituted urea derivatives for treating cardiac diseases |
| US7776869B2 (en) | 2004-10-18 | 2010-08-17 | Amgen Inc. | Heteroaryl-substituted alkyne compounds and method of use |
| EP1655296A1 (en) | 2004-10-25 | 2006-05-10 | Graffinity Pharmaceuticals AG | Thrombin inhibitors |
| EP1844062A2 (en) | 2005-01-21 | 2007-10-17 | Methylgene, Inc. | Inhibitors of dna methyltransferase |
| GB0517740D0 (en) | 2005-08-31 | 2005-10-12 | Novartis Ag | Organic compounds |
| US7825120B2 (en) | 2005-12-15 | 2010-11-02 | Cytokinetics, Inc. | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas |
| WO2007148738A1 (ja) | 2006-06-20 | 2007-12-27 | Ishihara Sangyo Kaisha, Ltd. | 新規なピリジル－メタナミン誘導体又はその塩を含有する有害生物防除剤 |
| US20080132525A1 (en) | 2006-12-04 | 2008-06-05 | Methylgene Inc. | Inhibitors of DNA Methyltransferase |
| JP2010517989A (ja) | 2007-02-01 | 2010-05-27 | アストラゼネカ アクチボラグ | Ｈｓｐ９０阻害剤としての５，６，７，８−テトラヒドロプテリジン誘導体 |
| US20090011994A1 (en) | 2007-07-06 | 2009-01-08 | Bristol-Myers Squibb Company | Non-basic melanin concentrating hormone receptor-1 antagonists and methods |
| WO2009034433A2 (en) | 2007-09-10 | 2009-03-19 | Glenmark Pharmaceuticals, S.A. | 3-azabicyclo [3.1.0] hexane derivatives as vanilloid receptor ligands |
| ES2446932T3 (es) | 2007-10-08 | 2014-03-10 | Advinus Therapeutics Private Limited | Derivados de acetamida como activadores de glucoquinasa, su procedimiento y aplicaciones en medicina |
| US8343966B2 (en) | 2008-01-11 | 2013-01-01 | Novartis Ag | Organic compounds |
| UY31952A (es) | 2008-07-02 | 2010-01-29 | Astrazeneca Ab | 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim |
| TW201028381A (en) * | 2008-07-14 | 2010-08-01 | Shionogi & Co | Pyridine derivative having ttk inhibition activity |
| TW201011017A (en) | 2008-08-19 | 2010-03-16 | Astrazeneca Ab | Chemical compounds 495-1 |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| AR074760A1 (es) | 2008-12-18 | 2011-02-09 | Metabolex Inc | Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico. |
| WO2010088518A2 (en) | 2009-01-31 | 2010-08-05 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| KR101146010B1 (ko) * | 2009-09-10 | 2012-05-16 | 서울대학교산학협력단 | ＴＮＦ-α 매개성 질환의 예방 및 치료용 조성물 |
| CN102686584A (zh) | 2009-11-13 | 2012-09-19 | 盐野义制药株式会社 | 具有氨基连接基的氨基噻嗪或氨基噁嗪衍生物 |
| WO2011079274A1 (en) | 2009-12-23 | 2011-06-30 | Jasco Pharmaceuticals, LLC | Aminopyrimidine kinase inhibitors |
| EP2516434B1 (en) | 2009-12-23 | 2015-05-27 | Takeda Pharmaceutical Company Limited | Fused heteroaromatic pyrrolidinones as syk inhibitors |
| EP2338888A1 (en) | 2009-12-24 | 2011-06-29 | Almirall, S.A. | Imidazopyridine derivatives as JAK inhibitors |
| US9073903B2 (en) | 2010-02-17 | 2015-07-07 | Jasco Pharmaceuticals, LLC | Imidazole-2,4-dione inhibitors of casein kinase 1 |
| WO2011150156A2 (en) | 2010-05-26 | 2011-12-01 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
| US9422262B2 (en) | 2010-09-24 | 2016-08-23 | The Broad Institute, Inc. | Compounds and methods for treating diseases mediated by protease activated receptors |
| US20120184572A1 (en) | 2011-01-13 | 2012-07-19 | Metabolex, Inc. | Aryl gpr119 agonists and uses thereof |
| WO2012099807A1 (en) | 2011-01-17 | 2012-07-26 | Karyopharm Therapeutics, Inc. | Olefin containing nuclear transport modulators and uses thereof |
| WO2012170931A2 (en) | 2011-06-10 | 2012-12-13 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| US20140256740A1 (en) | 2011-07-29 | 2014-09-11 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
| EP2736329A4 (en) | 2011-07-29 | 2015-03-25 | Tempero Pharmaceuticals Inc | COMPOUNDS AND METHODS |
| US20140357594A1 (en) * | 2011-10-24 | 2014-12-04 | Glaxosmithkline Intellectual Property (No.2) Limited | New compounds |
| US9013997B2 (en) | 2012-06-01 | 2015-04-21 | Broadcom Corporation | System for performing distributed data cut-through |
| JP6535430B2 (ja) | 2012-09-28 | 2019-06-26 | イグニタ、インク． | 非定型プロテインキナーゼｃのアザキナゾリン阻害薬 |
| CN106211771A (zh) | 2014-01-21 | 2016-12-07 | 沃克哈特有限公司 | 含氮化合物及其作为抗菌剂的用途 |
| WO2015110999A1 (en) | 2014-01-24 | 2015-07-30 | Piramal Enterprises Limited | Ezh2 inhibitors and uses thereof |
-
2017
- 2017-06-13 SG SG11201809559UA patent/SG11201809559UA/en unknown
- 2017-06-13 MX MX2018015483A patent/MX391600B/es unknown
- 2017-06-13 MA MA045244A patent/MA45244A/fr unknown
- 2017-06-13 CN CN201780036908.XA patent/CN109563043B/zh active Active
- 2017-06-13 CA CA3026226A patent/CA3026226A1/en not_active Abandoned
- 2017-06-13 US US16/309,121 patent/US10975056B2/en active Active
- 2017-06-13 CA CA3026211A patent/CA3026211A1/en active Pending
- 2017-06-13 PE PE2018003216A patent/PE20190971A1/es unknown
- 2017-06-13 KR KR1020197000766A patent/KR20190017030A/ko not_active Ceased
- 2017-06-13 CR CR20180580A patent/CR20180580A/es unknown
- 2017-06-13 ES ES17733902T patent/ES2993451T3/es active Active
- 2017-06-13 WO PCT/IB2017/053511 patent/WO2017216727A1/en not_active Ceased
- 2017-06-13 PH PH1/2018/502633A patent/PH12018502633B1/en unknown
- 2017-06-13 WO PCT/IB2017/053509 patent/WO2017216726A1/en not_active Ceased
- 2017-06-13 EP EP17733902.5A patent/EP3468953B1/en active Active
- 2017-06-13 AU AU2017283790A patent/AU2017283790B2/en not_active Ceased
- 2017-06-13 JP JP2019517187A patent/JP7051829B2/ja active Active
-
2018
- 2018-11-21 IL IL263163A patent/IL263163B/en unknown
- 2018-12-07 DO DO2018000273A patent/DOP2018000273A/es unknown
- 2018-12-10 JO JOP/2018/0120A patent/JOP20180120A1/ar unknown
- 2018-12-12 CL CL2018003577A patent/CL2018003577A1/es unknown
- 2018-12-18 CO CONC2018/0013717A patent/CO2018013717A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL263163B (en) | 2021-10-31 |
| CO2018013717A2 (es) | 2019-01-18 |
| JOP20180120A1 (ar) | 2019-01-30 |
| CA3026211A1 (en) | 2017-12-21 |
| CR20180580A (es) | 2019-07-02 |
| JP7051829B2 (ja) | 2022-04-11 |
| US20190194166A1 (en) | 2019-06-27 |
| ES2993451T3 (en) | 2024-12-30 |
| JP2019517596A (ja) | 2019-06-24 |
| KR20190017030A (ko) | 2019-02-19 |
| CA3026226A1 (en) | 2017-12-21 |
| BR112018075992A2 (pt) | 2019-04-02 |
| IL263163A (en) | 2018-12-31 |
| DOP2018000273A (es) | 2019-03-31 |
| WO2017216727A1 (en) | 2017-12-21 |
| PE20190971A1 (es) | 2019-07-09 |
| PH12018502633B1 (en) | 2023-02-01 |
| CL2018003577A1 (es) | 2019-04-05 |
| MA45244A (fr) | 2019-04-17 |
| PH12018502633A1 (en) | 2019-09-30 |
| EP3468953C0 (en) | 2024-05-22 |
| EP3468953A1 (en) | 2019-04-17 |
| MX2018015483A (es) | 2019-03-18 |
| AU2017283790B2 (en) | 2019-08-29 |
| CN109563043A (zh) | 2019-04-02 |
| SG11201809559UA (en) | 2018-12-28 |
| WO2017216726A1 (en) | 2017-12-21 |
| AU2017283790A1 (en) | 2018-11-22 |
| CN109563043B (zh) | 2022-05-31 |
| EP3468953B1 (en) | 2024-05-22 |
| US10975056B2 (en) | 2021-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20180120A1 (ar) | مشتقات بيريدين مستبدلة كمثبطات انتقائية لـ dnmt1 | |
| MX2023005636A (es) | Inhibidores de bcl6 derivados de bencimidazolona. | |
| PH12019500830A1 (en) | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer | |
| CY1121763T1 (el) | Παραγωγα διπυραζολιου ως αναστολεις jak | |
| MD4666B1 (ro) | Inhibitori ai Syk | |
| EA201690094A1 (ru) | Ингибиторы syk | |
| MY171577A (en) | 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication | |
| MX2015017861A (es) | Derivados de benzotiofeno como inhibidores del receptor de estrogeno. | |
| EA201690752A1 (ru) | Ингибиторы g12c kras | |
| EA201391098A1 (ru) | C-28-амины c-3-модифицированных производных бетулиновой кислоты в качестве ингибиторов созревания вич | |
| TR201904340T4 (tr) | Yeni bileşikler. | |
| PH12013501704A1 (en) | Substituted aminobutyric derivatives as neprilysin inhibitors | |
| MX2015010354A (es) | Derivados de acido betulinico modificados con aquilo c-3 y alquenilo utiles en el tratamiento de virus de inmunodeficiencia humana (vih). | |
| NZ726366A (en) | Syk inhibitors | |
| PH12014501283A1 (en) | 4`-azido, 3``-fluoro substituted nucleoside derivatives as inhibitors of hcv rna replication | |
| MA38803A1 (fr) | Nouveaux dérivés d'indolizine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
| CY1120608T1 (el) | Φαρμακευτικως δραστικες ενωσεις | |
| BR112015023222A2 (pt) | compostos tetraidroisoquinolin-2-il-(quinazolin-4-il)metanona como inibidores do crescimento de células cancerosas | |
| EA201990023A1 (ru) | Замещенные пиридины в качестве ингибиторов dnmt1 |